Incontinentia Pigmenti (IP) is an X-linked genodermatosis that is lethal for males and present in females with abnormal skin pigmentation and high variable clinical signs, including retinal detachment, anodontia, alopecia, nail dystrophy and nervous system defects. The NF-kB essential modulator (NEMO) gene, responsible for IP, encodes the regulatory subunit of the IkB kinase (IKK) complex required for nuclear factor kB (NFkB) activation. We analyzed the NEMO gene in 122 IP patients and identified mutations in 83 (36 familiar and 47 sporadic cases). The recurrent NEMO exon 4 -10 deletion that is the major cause of the disease was present in 73 females (59.8%). In addition 10 point alterations (8.2% of females) were identified: three frameshift, three nonsense, three missense and one in-frame deletion of a single amino acid. We measured the effects of these NEMO point-mutations on NF-kB signaling in nemo(2/2) deficient murine pre-B cells. A mutation in the N-terminal domain, required for IKK assembly, reduced but did not abolish NF-kB activation following lipopolysaccharide stimulation. Mutations that disrupt the C-terminal domain, required for the recruitment of upstream factors, showed lower or no NF-kB activation. A phenotype score based on clinical features of our IP patients was applied for summarizing disease severity. The score did not correlate with mutation type or domain affected indicating that other factors influence the severity of IP. Such a factor is likely to be X-inactivation. Indeed, 64% of our patients have extremely skewed X-inactivation pattern (!80 : 20). Overall IP pathogenesis thus depends on a combination of X-inactivation and protein domain that recruit upstream factors and activate NF-kB.
INTRODUCTION
Incontinentia Pigmenti (IP) is a rare X-linked dominant genodermatosis, lethal for males during embryogenesis. Heterozygous females can instead survive owing to X-inactivation mosaicism. Abnormal skin pigmentation, retinal detachment, anodontia, alopecia, nail dystrophy and nervous system defects are all characteristic signs of IP (1) . Currently, early diagnosis of IP is based on the presence of abnormal skin pigmentation that evolves in four dermatological stages. Again on the basis of X-chromosome mosaicism selection, it disappears by the second decade and adults may retain only areas of dermal atrophy.
The gene responsible for IP encodes the 48 kDa NF-kB essential modulator (NEMO) protein, also referred to as IKKg, which is the essential modulator of nuclear factor kB (NF-kB) (2, 3) . NEMO serves as a scaffolding subunit that binds two proteins with kinase activity (IKKa and IKKb), necessary for NF-kB activation (4) . In resting cells, NF-kB homoand heterodimers are sequestered in the cytoplasm through Human Molecular Genetics, Vol. 13 *To whom correspondence should be addressed. Email: ursini@igb.cnr.it { The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.
Human Molecular Genetics, 2004, Vol. 13, No. 16 1763-1773 doi:10.1093/hmg/ddh192 Advance Access published on June 30, 2004 interaction with one or more inhibitory proteins, the IkBs. After stimulation by many known stimuli, IkB is phosphorylated by the IkB kinase (IKK) complex and promptly degraded by the ubiquitin -26S proteasome pathway (5, 6) . NF-kB then can shuttle to the nucleus, where it activates target-gene transcription. NEMO contains two coiled-coil motifs (CC1 and CC2) and a leucine zipper (LZ) domain, required for IKKã -IKKb association and its oligomerization, and a zinc finger (ZF) domain at the C-terminus required for the recruitment of upstream factors but not for complex assembly (2, 3) . NEMO is known to be the only subunit absolutely required for the activation of the IKK complex, but only some features of its action are well understood. Thus, it appears that NEMO is the point of convergence for many NF-kB activation pathways, including those induced by TNF-a, IL-1, lipopolysaccharide (LPS) or other proinflammatory cytokines and by dsRNA (4, 6) .
nemo-deficient mice recapitulate features of human IP disease (7) (8) (9) . Male mutant mice die prenatally, even earlier than other mice with mutated NF-kB signaling proteins, because of dramatic liver degeneration due to TNF-a induced hepatocyte apoptosis. Female mice develop IP-like skin lesions with granulocyte infiltration, hyperkeratosis and increased apoptosis. Although many female mice die during these inflammatory stages, some survive and are fertile. The death and clearance of nemo-deficient cells probably account for this recovery.
Additional genetic studies revealed that IP is allelic with an X-linked immunodeficiency syndrome termed hypohidrotic ectodermal dysplasia with severe immunodeficiency (EDA-ID), which, unlike IP, is associated with specific developmental and immunological defects in males (10) . It was proposed that loss-of-function mutations in NEMO were associated to IP, whereas NEMO hypomorphic mutations, which did not severely reduce NF-kB activation, were associated with EDA-ID (10 -12) .
Owing to the ubiquitous nature of the NF-kB pathway, clinical manifestations of IP show a large phenotypic range, (15) . Black symbols represent the clinical signs of each mutated NEMO patient as described in the legend.
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Human Molecular Genetics, 2004, Vol. 13, No. 16 from simple cutaneous manifestations to neurological problems. The signaling pathways that lead to activation of NF-kB via the IKK complex differ among tissues, and may use different mechanisms to activate NEMO. The availability of natural NEMO mutants should therefore provide important clues about its functions and the molecular mechanism that leads to IP. Previous data reported by us and others (13 -15) revealed that an identical genomic deletion within NEMO account for the majority of identified mutations and that the remaining mutations are small duplications, substitution or deletion, scattered all along the gene. However, most of the small mutations previously described produce early truncated NEMO protein, precluding any analysis of the correlation between the protein domain affected, the efficiency of the NF-kB activation process and the phenotype presentation (15) .
Here, we report a mutational analysis of the NEMO gene in a large, clinically well characterized cohort of 122 unrelated IP patients. We measured the effects of these NEMO pointmutations on NF-kB signaling in nemo-deficient murine pre-B cells. A phenotype score was also applied to the clinical feature of our IP patients, and skewed X-inactivation pattern in their peripheral blood cells was measured. NEMO mutations we have isolated in this study account for the majority but not all clinical cases; moreover, the detected mutation spectrum do not allow genotype-phenotype correlation, leading to the hypothesis that other factors may modulate the IP pathogenesis.
RESULTS

NEMO mutations in IP patients
We performed a mutational analysis of NEMO, a 23 kb gene composed of 10 exons (GenBank accession no. AJ271718) (13) (Fig. 1) , in a cohort of 122 patients diagnosed with IP. We found a recurrent NEMO deletion (exons 4-10) in 73 out of 122 patients (59.8%) using the polymerase chain reaction (PCR) test as described by Bardaro et al. (14) (Table 1) . Among these, 39 (53%) appeared to be de novo mutations in isolated cases with no family history of IP.
In 49 (40.2%) IP patients that did not show the recurrent deletion, denaturing high performance liquid chromatography (DHPLC) analysis of all coding exons (exons 2 -10) revealed 10 point-mutations in 10 unrelated patients (8.2%) ( Table 2) . Sequence tracings of the described mutations and all the pedigrees are shown in Figure 2 . Seven of them were sporadic cases suggesting that the mutations were generated as de novo alterations. DNA analysis of parents of IP females revealed abnormalities in only three cases: the mother of patient 1-SA (E57K), the mother of patient 4-PB (R123W) and the mother of patient 8-MF (E315GfsX393). These mothers showed only mild dermatological signs, compatible with diagnosis of IP. Among the 10 small nucleotide changes, eight of them had not been described previously. Specifically, three are missense mutations (E57K, D113N and R123W in patients 1-SA, 3-LE and 4-PB, respectively), three are nonsense mutations (R62X, Q239X and Q384X in patients 5-SE, 6-RE and 7-TE, respectively), one is a single-nucleotide insertion (E315GfsX393 in patient 8-MF), two are single-nucleotide deletions leading to frameshift (H360MfsX449 and P372PfsX450 in patients 9-SA and 10-CL, respectively) and one is an in-frame deletion of a codon resulting in one amino acid microdeletion (DK90 in patient 2-DA). We subdivided these NEMO point-mutations in different groups, according to their effect on the predicted protein (NCBI ORF finder, Fig. 3 ). The first class comprises mutations affecting the N-terminal and CC1 domains (group A) (Fig. 3, protein translations 1 -4) . Specifically, the patient 1-SA carries a transition 169G ! A (E57K) that was already described (15) ; the patient 2-DA carries an in-frame Mutations described in the group C (Fig. 3 , protein translations 8 -10) include two frameshift mutations that alter only the LZ and the ZF domains, producing proteins with complete CC1 and CC2 domains but lacking the LZ and ZF (shorter protein, translation 8) or complete CC1/2 and LZ domains (elongated protein, translations 9 and 10). The 943 -944insG (E315GfsX393), identified in the patient 8-MF, causes a frameshift that leads to a mutated LZ domain and completely removes the putative ZF domain located at the extreme C-terminus of the NEMO protein. Two small deletions (1077 -1078delC, 1115-1116delT) within the same region upstream the ZF domain causes a frameshift and a premature stop codon 89 and 78 in patients 9-SA and 10-CL, respectively.
We identified mutations in 83 of 122 cases with classical IP (32%). In addition, we analyzed the NEMO coding region, but neither changes in the promoter region nor large DNA rearrangement or deletions were assessed. Gross gene deletions and rearrangements have been commonly observed in patients with other X-linked diseases such as Duchenne muscular dystrophy and haemophilia A (16, 17) . Therefore, although locus heterogeneity remains a possibility in IP, any other gene(s) involved would only account for a minor proportion of classical IP cases.
Functional analysis of NEMO mutations
To investigate the functional relevance of the small NEMO mutations reported here, we used a cis-reporter luciferase plasmid that provides a simple and rapid assessment of the in vivo activation of the NF-kB pathway. The reporter pIgkLuc plasmid expresses the luciferase gene downstream three NF-kB binding sites. We used site-directed mutagenesis to generate recombinant plasmids containing NEMO cDNAs carrying each of the nine small mutations isolated in our IP cohort (only R62X was not included in the analysis) in the pcDNA3 vector. We examined the ability of these NEMO mutants to restore the NF-kB activation in reconstituted mouse 1.3E2 cells [nemo 2/2 murine pre-B lymphocytes (18)], measuring the luciferase activity, after LPS stimulation. LPS is the principal component of Gram-negative bacterial wall, which activates the innate immune system inducing the NF-kB pathway via the Toll-like receptors (19) . The luciferase activity generated by the DK90 mutation, affecting the CC1 domain, was only 46.3% of the activation obtained with NEMO WT protein, whereas NEMO E57K, NEMO D113N and NEMO R123W showed the same luciferase activity as the control ( Fig. 2 ; protein activity column). In contrast, the mutations eliminating the CTS domain (Q239X, E315GfsX393 and H360MfsX449) exhibited little or no NFkB activation (0, 0 and 3.4%, respectively). Only the Q384X mutation, that preserves the complete CC2 and LZ domains, retained 37.5% of the NEMO WT activation.
Interaction of the mutant NEMO protein in the IKK complex
We examined whether IKKa and IKKb could still physically interact with the mutant NEMO proteins. In particular, we tested the ability of two mutations falling in the coiled-coil domain 1, DK90 and D113N, to associate with IKKs. HEK 293T cells were cotransfected with combinations of the empty vector (pcDNA3) or DK90 and D113N constructs with either FLAG -IKKa or FLAG -IKKb plasmids. Cell extracts were immunoprecipitated with an anti-FLAG antibody and then analyzed by immunoblotting assay with an anti-NEMO (Fig. 4) . We found that IKKb immunoprecipitation brought down less DK90 mutant protein compared with WT NEMO, consistent with the DK90 mutant having lower affinity for IKKb, whereas the amount of immunoprecipitated D113N was perfectly comparable with the amount of immunoprecipitated WT NEMO (Fig. 4B) . These results confirm that D113N is a polymorphic functional variant of the NEMO protein. Interestingly, the same kind of experiment performed using a FLAG -IKKa did not reveal any defect in the amount of immunoprecipitated DK90 NEMO, suggesting that the observed defect was IKKb specific (Fig. 4A ).
Genotype -phenotype correlation
Comprehensive phenotype data were available on a total of 60 IP patients, 50 of which carrying genomic deletion and 10 with point-mutations. We evaluated the clinical features and correlated the mutation type with clinical traits involving NS, eyes, teeth, hair and nails that, indeed, are the most frequent pathological signs observed among IP patients. Moreover, all tissues involved in IP are derived from the neural crest and thus have the same neuroectodermal derivation. The abnormal skin pigmentation, that was present in all patients, was not included. On the basis of the clinical data, a phenotypic severity score was calculated for each patient, summarizing the pathologic clinical features (Tables 1 and 2 ). Patients carrying mutations DK90 and H360MfsX449 (Table 2 , patients 2-DA and 9-SA, respectively) have been found to have higher values for the combined score (score 7 and 5, respectively) and therefore suffered more severe disease than patients with missense mutations (score 0 for 1-SA, E57K, and 4-PB, R123W) or those with a nonsense mutation (score 0 for 6-RE, Q239X and 2 for 7-TE, Q384X). Moreover, the patient 10-CL, carrying the mutation P372PfsX450 showed a phenotype score of 4. High variability of the phenotype scores was observed in patients carrying the mutation Dexon4 -10 ( Table 1) . Eleven patients (22%) showed a very high score (score 3 -8); six (12%) showed two clinical features combination (score 2); 33 (66%) had one pathologic character (score 1) or showed only abnormal skin pigmentation (score 0). Nervous system defects were observed in 44% of patients carrying point-mutations and ocular defects in 55% of patients, whereas only 8% of IP patients with genomic deletion suffered nervous system defects and 16% had ocular defects. Human
X-Inactivation studies
X-Inactivation studies were performed on peripheral blood of 53 IP patients. The age of patients included in this analysis was restricted to those of 25 years of age or younger, as skewing is known to increase with age (20, 21) . Using the androgen receptor (AR) X-inactivation assay, we determined the X-inactivation pattern of all female subjects (41 carrying the Dexon4 -10 deletion, 12 point-mutations, including three carrier mothers). The frequency of X-inactivation pattern for single classes of value is shown in Table 3 . An X-inactivation pattern ,80 : 20 is demonstrated in 100% of control females, which is generally consistent with previous estimations (22) . In contrast, 64.1% of IP patients show X-inactivation patterns that were !80: 20 (Table 3 ) and 45.3% have X-inactivation values !90: 10%. Totally, 31 of these patients have Dexon4 -10 mutation and three have a point-mutation. We also examined the X-inactivation pattern in peripheral blood of three families each having a daughter carrying a point-mutation (E57K, R123W and E315GfsX393). All the mothers have the same mutation as their daughters and show a moderately skewed X-inactivation profile. Furthermore, we tested the X-inactivation pattern in the sister of the patient with the point-mutation E315GfsX393 and we found it is severely skewed (97 : 3%). This large deletion results from slipped mispairing between two identical MER67B repeated sequences (13) . The remaining 12.1% of the mutations found in our patients are small nucleotide substitutions, deletions and insertions (15) . Only one missense mutation was identified as a conservative substitution (D113N patient 3-LE Fig. 2 ). Among the 122 IP patients analyzed here, 47 were sporadic cases.
DISCUSSION
As previously reported (15), small mutations are scattered along the NEMO gene, consistent with the importance of the entire NEMO protein sequence for its function. Interestingly, all the single-nucleotide substitutions are C ! T transitions (or G ! A when the 5-methylcytosine deamination occurs on the antisense strand), three of them occurring at CpG sites. Protein activity is obtained in a complementation assay. NTS, N-terminal sequence; CTS, C-terminal sequence; CC1, coiled-coil domain 1; LZ, leucine zipper domain; fs, frameshift; stop, stop codon; PBL, peripheral blood leucocytes. n.t., no tested.
They were probably caused by methylation of a cytosine residue to 5-methylcytosine that predisposes by spontaneous deamination to thymidine. In many cases germ-line CpG transition mutations show a male predominance (23), and we hypothesized that the majority of de novo NEMO mutations described here leading to IP arise from 5mC ! T deamination in male germ cells. Previous reports have indicated a 2-fold increase in male germ cells occurrence of new IP mutations (10/5 male : female ratio), and a high male : female ratio of germ-line mutations has been measured in other X-linked genetic disorders such as haemophilia A and B (23, 24) , and suggested for Rett syndrome (25) . On the basis of the high de novo mutation rate reported here, we suspect that the prevalence of IP (1 : 10 000/20 000) is underestimated.
Functional analysis of NEMO mutants
We analyzed the effect of the NEMO mutations on NF-kB activation, using LPS as a stimulus. Three NEMO mutant polypeptides lack the putative ZF domain, located at the C-terminal extremity, that is required for the binding of the IKK complex to upstream activators and for the subsequent NF-kB activation. In two of them (H360MfsX449 and P372PfsX450), a frameshift mutation causes the production of polypeptides longer than the WT (the wild-type protein is 417 amino acids, whereas these mutated protein are 449 and 450 amino acids, respectively). We have evaluated the functional consequences of H360MfsX449 that severely impaired NF-kB activity (3.4%). The third predicted mutant polypeptide (Q384X), truncated at codon 384, restore 37.5% of the WT NF-kB activity. The different extent of NF-kB activation observed between the different types of mutants without ZF (from 37.5 to 0%) may result from decreased stability of the NEMO polypeptides with incorrect amino acid sequences.
The two mutations that disrupt both LZ and ZF domains produce a protein truncated at position 239 or a protein with frameshift from position 315 (Q239X and E315GfsX393). These products did not show any detectable LPS induction in vitro (Fig. 3) . The impaired NF-kB activation could be due to the inactive NEMO protein and also due to reduce NEMO mutant expression.
The four missense mutations found in our cohort of IP patients all fall in the CC1 domain and could affect a region required for binding IKKa and IKKb into a high-molecular weight complex essential for kinase activity. D113N is a conservative substitution and, in fact, rescues 100% of the NF-kB activity. Of the remaining three mutations, only DK90 exhibited a reduced NF-kB activation (46.3%) in our luciferase assay, based on the use of LPS as the stimulus. E57K and R123W may nevertheless be defective in other signaling pathways, such as the one used by IL-1 or TNF-a. Concerning IL-1, this is unlikely, as this cytokine acts through a receptor that recruits the same signaling molecules as TLR4, the LPS receptor (19) . In the case of TNF-a, the analysis cannot be done using 1.3E2 mutant cells as the wt cells they are derived from, 70Z/3, lack TNF-R expression (26) . To analyze this pathway, and others that may contribute to the IP disease, we are currently trying to use other NEMO(2) cells, such as NEMO(2) MEFs (9) .
Mutations in different domains of the NEMO protein could also affect interaction with tissue-specific intracellular transducers and thus produce tissue-specific defects. Indeed, evidence is emerging that NF-kB pathway has a critical role in CNS in processes such as neuronal plasticity, neuro-degeneration and neuronal development (27) . In this respect it is noteworthy that, most of the mutations described here are associated with severe NS and ocular defects including seizure, mental retardation and microcephaly, which are generally considered as developmental defects (28, 29) .
A critical role for NEMO activity is in the formation of functional IKK complex. Interestingly, DK90 NEMO, which lacks a residue presumably involved in IKK complex assembly, still retains the ability to interact with IKKa but exhibit a reduced interaction with IKKb. As it has been shown that NEMO interacts with both IKKa and IKKb , but that the two catalytic subunits do not play the same role in vivo, the DK90 NEMO protein might generate a shift from IKKa -IKKb -NEMO complexes to IKKa -IKKa -NEMO complexes, which (10) would disturb the NF-kB activation process. We are in the process of generating cells stably expressing DK90 to verify this hypothesis. In summary, NEMO mutations described here affect the NF-kB activation after LPS triggering. However, this effect is much more evident in C-terminal disease-linked mutations producing truncated protein than in N-terminal diseaselinked mutations, which are mainly missense changes that only slightly affect the NF-kB activity. This is in agreement with the previously reported in vitro data on NEMO functional analysis, which suggested that the C-terminus of NEMO protein contains interaction domains that are absolutely required for connecting the IKK complex to the upstream activators (3).
The relevant incidence of hypomorphic mutations found in our IP patient cohort (11%) somewhat modifies the general assumption that IP is caused only by NEMO loss-of-function mutation. In addition, many of the mutations responsible for IP map near to the mutations identified in EDA-ID patients (12) , which mainly affect the C-terminal domain. Thus, similar mutation can cause two clinically distinct diseases: EDA-ID in hemizygous males and IP in heterozygous females.
Genotype -phenotype correlation and X-inactivation analysis in IP patients
A phenotype scoring system was used for examining correlation between the mutation type and the clinical presentation of IP patients. To assess genotype -phenotype correlation in IP patients, we listed features that are typical for IP but not consistent in all patients and could therefore reflect the severity of the syndrome (Tables 1 and 2 ). For calculating the score we included only defects relative to nervous system, eyes, teeth, hair and nail, that are most frequently, but not always, observed in IP patients. We did not include in the score calculation abnormal skin pigmentation, that is present in all patients. If a genotype -phenotype correlation does exist, females who carry loss-of-function mutations would be expected to have the most severe phenotype. In our study, however, this is not the case: 50 patients with the same exon 4-10 NEMO deletion have severity score ranging from 1 to 8. In addition, at the milder end of the spectrum we would expect to find patients who carry missense mutations that only slightly affect NEMO function. Patient 1-SA (E57K) fulfils these criteria, indeed she has a mild phenotype (score 0). In contrast, patient 2-DA (DK90) is severely affected (score 7). We have also documented cases of females carrying the same point-mutation but presenting a different clinical picture (patient 8-MF, pedigree in Fig. 2 ). Factors that may influence the phenotype include the X-inactivation pattern.
To get insights about the X-inactivation status we measured skewing in peripheral blood lymphocytes (PBL) from 52 patients. In general, the observed incidence of skewing in our cohort of IP patients is 76.4%, higher than would be expected in a normal population with a maximum age of 25 (20, 21) . A higher degree of skewing (100%) has been observed in association with the common rearrangement as well as with the truncating mutation (R62X), which causes loss-of-function of NEMO, whereas for the mutations that still retain some activity, such as DK90 and Q384X, the X-inactivation value decreased (73 and 65%, respectively). We hypothesize that cells expressing the mutation that preserves some NEMO activity (hypomorphic mutations) may still be partially active early after the X-inactivation process and would survive while cells expressing loss-of-function NEMO mutations would disappear preferentially after X-inactivation. This would also explain the high prevalence of skewed X-inactivation observed in IP patients with loss-of-function or early truncating mutations ( Fig. 3 and R62X) . The case of the female patient carrying the D113N polymorphic NEMO variant deserves particular attention, as it has full functional activity and was found to be 99% skewed. We may hypothesize that this patient is also carrying an additional NEMO mutation (rearrangement, mutation in regulatory regions, etc.) escaping from our molecular analysis but causing the skewed X-inactivation.
We also found that mutations preserving some activity show an atypical phenotype characterized by involvement of much more tissues than classical IP phenotype. This is true for DK90 and for the two frameshift mutations at the C-terminal end of the NEMO protein, 1077 -1078delC and 1115 -1116delT (score 5 and 4, respectively). Those NEMO mutations are associated with more severe NS and ocular defects than those associated with exon 4 -10 deletion mutation. Hypomorphic mutations thus may have broader phenotypic consequence than typical IP, in which skewed X-inactivation is likely to modulate the severity of the disease. Aradhya et al. (15) proposed this same interpretation of the data on the basis of a molecular analysis of NEMO mutation in a large cohort of IP patients. However, in that case phenotypic variability of IP presentation was not corroborated by functional data as the spectrum of mutations described there included most mutations prematurely disrupting NEMO protein.
In summary, although X-inactivation is likely to play a role in modulating the pathogenic effects of different mutations, the X-inactivation performed on PBL cannot allow us to draw any conclusion about the skewed X-inactivation in other tissues that show pathological sign. However, PBL serve as a phenotypic surrogate for cells in the affected tissue as for example central nervous system, eye, etc. Accordingly, NEMO mutants associated with skewing might affect in vivo cell viability and proliferation in many tissue types including PBL. We hypothesize that IP may arise precisely in those cells that survive with partial NEMO function, as in developing brain after early neuronal plasticity is lost. This is in contrast with those cases in which the NEMO activity is absent, where dysfunctional cells are lost and their function is taken over by their WT neighbors. The variability in IP phenotypes would then result from a combination of the type of mutation, the functional domain affected and X-inactivation.
MATERIALS AND METHODS
Patients
All the IP patients we analyzed in this study met the 1993 revised criteria for classification of IP (1) . All patients' material was gathered, after receiving informed consent from participants, under protocols approved by the Declaration of Helsinki. Each potential participant with IP was interviewed and asked to complete an extensive questionnaire. Only 60 questionnaires were available. All medical records of IPaffected family members were reviewed to confirm the diagnosis. The affected females had a history of perinatal blistering and at least one of the other stages of skin lesions. Blood samples were collected in EDTA tubes and genomic DNA was extracted using conventional salt precipitation technique. All patients had an apparently normal karyotype. On the basis of the geographic records of our cohort of IP patients, we established their origins from the following countries: Brazil, Czechoslovakia, Italy, Ireland, Poland, Portugal, Spain, Switzerland, Turkey and UK.
Mutation detection
PCR amplification of IP patients was carried out in a reaction volume of 12 ml with 100 ng of template genomic DNA for each exon with previously reported primers (14) . DHPLC analysis was performed according to the manufacturer's protocol (30) . Samples showing an abnormal chromatogram were further analyzed by direct sequencing using Big Dye Terminator Cycle Sequencing Reactions on an ABI 3100 (PE Applied Biosystems). Sequence electropherograms were compared with the genomic sequence from GenBank and control samples. Potentially pathogenic changes were validated by DHPLC analysis of 120 normal control females. If the change was not present in control chromosomes, we analyzed samples from IP family members, when available. PCR conditions, primer sequences and DHPLC analysis conditions are available upon request.
To investigate the NEMO gene deletion (D4 -10 exons), a long-range PCR was performed with the EXPAND Long Template PCR system (Roche Mannheim, Germany) according to the manufacturer's protocol. The specific primers for the long-range PCR are reported in Bardaro et al. (14) .
Mutation nomenclature
Nucleotides were numbered from the first base of the translation initiation ATG codon (BC050612) according to Aradhya et al. (15) . Mutations were described as recommended by the ad hoc committee on mutation (31).
Site-directed mutagenesis and plasmids
The full-length human NEMO cDNA was inserted between the Hind III and Not I sites of the pcDNA3 vector (Stratagene, CA, USA). We generated plasmids carrying the point-mutations found in IP patients using the Quick-change site-directed mutagenesis kit (Stratagene). The sequence of all the mutated constructs was checked by automatic directed sequencing, using T7 and Sp6 primers.The FLAG -IKKb expression vector (pCMV-F-IKK2) was kindly provided by F. Mercurio (32) .
Transfection and complementation assay The 1.3E2 (nemo 2/2 murine pre-B lymphocytes) cells were grown in RPMI 1640 supplemented with 10% fetal calf serum (FCS) and 50 mM b-mercaptoethanol. The 1.3E2 cells were transiently transfected with the wt NEMO plasmid and all the mutant constructs by a modified DEAE -dextran method described in Courtois et al. (18) . The following day they were stimulated for 6 h with LPS (Sigma) and finally lysed in a luciferase buffer [25 mM Tris -phosphate (pH 7.8), 8 mM MgCl 2 , 1 mM DTT, 1% Triton X-100, 15% glycerol]. Luciferase determination was carried out using a Berthold luminometer (Berthold Detection Systems, Germany).
HEK293T cells were grown in DMEM supplemented with 10% FCS. HEK293T cells were transfected using calcium phosphate (33) . Briefly, the day before transfection, cells were plated in a 6-multi-well at density of 1.5 Â 10 5 cells in DMEM without FCS. The day after cells were transfected using 1 mg of pcDNA3-NEMOwt, NEMO (DK90) or NEMO (D113N) and 1 mg of either pCMV-F-IKKa or pCMV-FIKKb. Cells were recovered and cytoplasmic extracts were prepared, 24 h after transfection.
Immunoprecipitations and western blot analysis
Cells extracts from HEK293T were prepared as described elsewhere (2) . They were resuspended in 1 ml of TNT buffer [20 mM Tris (pH 7.5), 200 mM NaCl, 1% Triton X-100]. Anti-FLAG (Sigma -Aldrich) was added, and the samples were gently rocked at 48C for 1 h. A 20 ml volume of protein A -sepharose (Calbiochem, Germany), previously equilibrated in TNT, was added, and the incubation was continued for 30 min. After three washes in TNT (30 s in a microgentrifuge), the beads were resuspended in 1ÂLaemmli buffer, containing 10% b-mercaptoethanol, and boiled for 5 min. The samples were fractionated on sodium dodecyl sulfate-10% polyacrylamide gels and transferred to nitrocellulose membranes. Western blot was performed using an anti-NEMO antiserum (2) diluted 1: 4000 in 0.3% milk/PBS. The IKKa construct was kindly provided by F. Mercurio.
Phenotype analysis
A phenotype score of clinical severity was derived by assessing: (a) a score of 0 in the absence of extracutaneous complications; (b) a score of 1 for nervous system (NS) defects (seizures, spastic paresis, motor retardation, mental retardation or microcephaly); (c) a score of 1 for ocular system defects (strabismus, cataracts, optic atrophy, retinal vascular pigmentary abnormalities, microphtalmous or pseudogliomas); (d) a score of 1 for dental system defects (partial anodontia, delayed dentition, cone/peg shaped teeth or impactions); (e) a score of 1 for hair defects (vertex alopecia, wooly hair naevus or eyelash and eyebrow hypogenesis); (f) a score of 1 for nail defects (onychogryphosis, pitting or ridging). When the score was !2 for each system/organ the patient suffered by !2 clinical manifestations for that system/organ. The phenotype severity score allocated represents the addition of the single values of score for each system/organ.
X-Inactivation analysis
XCI patterns in the patients' blood lymphocytes was determined by PCR amplification of the AR locus, a polymorphic region of the X-chromosome containing different numbers of CAG repeats. The AR locus is consistently methylated on the inactive X-chromosome, making it inaccessible to digestion by the methylation-sensitive restriction enzyme Hpa II (New England Biolabs, USA) (34). Genomic DNA from IP patients and from both her parents were digested or not with Hpa II. Both digested and undigested DNA were PCR-amplified using primers that amplify a 280 bp product from the AR gene. Digestions and PCR were performed as described in Schanen et al. (35) . The PCR products were separated on an automatic sequencer (MegaBACE TM 1000-Amersham Biosciences, by BioGeM gene expression service). The peak heights were calculated according to Hammer et al. (36) .
